Clinical trial of targeted therapy for pediatric Hodgkin lymphoma shows excellent outcomes,

This phase 2 clinical trial replaced the chemotherapy drug vincristine with brentuximab vedotin in the frontline (first therapy given) treatment regimen., This phase 2 clinical trial replaced the chemotherapy drug vincristine with brentuximab vedotin in the frontline (first therapy given) treatment regimen., Read More

Scroll to Top